Celcuity (CELC) Stock
Cancer diagnostics company matching patients to treatment options. Here's the price, business snapshot, and what's worth knowing about Celcuity in August 2026.
Celcuity Inc (CELC) is a clinical-stage diagnostics company focused on precision oncology. The business works on identifying and validating biomarkers and developing assays that aim to help match cancer patients with targeted therapies or clinical trial options. Investors typically watch clinical data readouts, regulatory progress and any partnerships with pharmaceutical companies, as these milestones can influence future commercial potential. With a market capitalisation around $2.8 billion, Celcuity is relatively small and may exhibit significant share-price volatility. As with any early-stage healthcare company, risks include clinical setbacks, regulatory hurdles and funding needs. This summary is for educational purposes only and not personalised investment advice; values can rise or fall and past performance is not a guide to future results. Consider seeking independent financial or medical advice to assess suitability for your circumstances.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying CELCUITY's stock with a target price of $117.67, indicating high potential growth.
Financial Health
Celcuity Inc. is producing strong cash flow and has a solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Precision oncology focus
Works on biomarkers and assays to better match patients with therapies; scientific breakthroughs could drive upside, though clinical success is uncertain.
Partnership potential
Collaborations with pharma could accelerate development and commercialisation, but such deals typically depend on positive trial and regulatory outcomes.
Early-stage risks
Clinical, regulatory and funding risks can cause significant share-price swings; this profile may suit investors prepared for high volatility.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.